Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Candesartan cilexetil
Drug ID BADD_D00347
Description Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00796
KEGG ID D00626
MeSH ID C077793
PubChem ID 2540
TTD Drug ID Not Available
NDC Product Code 62559-641; 70771-1207; 17228-0032; 0378-3224; 46708-341; 62559-642; 63629-2126; 62332-341; 62332-342; 68382-191; 68382-193; 70771-1205; 52562-100; 46708-342; 0378-3232; 70771-1206; 46708-060; 46708-343; 60687-119; 60687-130; 62332-343; 17228-0016; 64220-114; 49884-659; 68382-190; 17228-0017; 65372-1128; 49884-658; 63629-2127; 68382-192; 70518-2719; 70518-2884; 60687-241; 62332-060; 62559-643; 0378-3225; 70771-1204; 17228-0018; 72761-002; 49884-661; 62559-640; 0378-3231; 49884-660
UNII R85M2X0D68
Synonyms candesartan cilexetil | 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate | 1H-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)- | Parapres | Kenzen | Amias | Blopress | Atacand | TCV 116 | TCV-116
Chemical Information
Molecular Formula C33H34N6O6
CAS Registry Number 145040-37-5
SMILES CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC 6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyslipidaemia14.08.04.015--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.0120.001262%Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000841%Not Available
Angiopathy24.03.02.007--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Cardiac disorder02.11.01.0030.002523%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Foetal disorder18.03.02.0010.008410%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation10.02.01.089; 08.01.05.0070.002944%Not Available
Limb discomfort15.03.04.014--Not Available
Ischaemic stroke24.04.06.010; 17.08.01.0180.001262%Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.009588%
Feeling of body temperature change08.01.09.0120.001262%Not Available
Erectile dysfunction21.03.01.007; 19.08.04.0010.001682%
Respiratory disorder neonatal18.04.09.002; 22.11.01.0020.000841%Not Available
Blood disorder01.05.01.004--Not Available
Adverse drug reaction08.06.01.009--Not Available
Bone lesion15.02.04.0160.000841%Not Available
Drug intolerance08.06.01.013--Not Available
Diabetic nephropathy20.05.03.011; 14.07.02.003; 05.07.02.003--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Urine analysis abnormal13.13.02.008--Not Available
Renal impairment20.01.03.0100.004794%Not Available
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Cystitis noninfective20.03.02.001--
Skin haemorrhage24.07.01.103; 23.06.07.0010.001262%Not Available
The 14th Page    First    Pre   14 15 16    Next   Last    Total 16 Pages